AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03727308 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medical abortion pills sourced from health clinics
Description: One cohort using medical abortion pills sourced from health clinics
Study NCT02390505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Study NCT02390505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03646461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560mg PO daily (Imbruvica)
Description: BTK inhibitor combined with PD-1 inhibitor
Study NCT03646461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
Study NCT03646461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg biweekly 28 day cycle
Study NCT04413006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion for Chronic Pain Virtual Group Treatment Program
Description: 6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
Study NCT00888732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
Description: 0.2 U/IU/kg subcutaneous injection, single dose
Study NCT06433492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection
Description: Three doses of intra-articular injection administered in weekely intervals.
Study NCT03052426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergotron WorkFit - TL
Description: A sit to stand work station.
Study NCT04036396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Enhanced Prevention Support
Description: Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
Study NCT04036396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care plus Customized Referrals
Description: Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
Study NCT04036396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care plus Customized Referrals
Description: Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
Study NCT04472832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Treatment A
Description: 6 tablets matched to mitapivat tablet
Study NCT04472832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat 100 mg
Description: Two 50-mg tablets
Study NCT04472832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Treatment B
Description: 4 tablets matched to mitapivat tablet
Study NCT04472832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat 300 mg
Description: Six 50-mg tablets
Study NCT04472832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Treatment C
Description: 4 tablets matched to mitapivat tablet
Study NCT04473677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The new qFIT and colonoscopy with pathological examination
Description: Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
Study NCT02167139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab)
Study NCT02167139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB5 (proposed biosimilar to adalimumab)
Study NCT02167139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB5 (proposed biosimilar to adalimumab)
Study NCT02462915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration.
Study NCT02462915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endotracheal tube
Description: traditional and regularly use in many surgeries for maintaining the airway.
Study NCT02462915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, propofol, fentanyl and cisatracurium
Study NCT01567709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01567709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01567709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01567709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01243580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-Cyclen
Description: Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
Study NCT01243580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
Study NCT03112577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Intravenous (IV) use
Study NCT03112577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous (SC) use
Study NCT03112577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT03112577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhalation use
Study NCT02711709 — intervention group
Intervention type: OTHER
Intervention: Frailty Measurements
Description: A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~1. muscle weakness~2. fatigue~3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months.
Study NCT02711709 — intervention group
Intervention type: OTHER
Intervention: Modified Minnesota Leisure Time Activities
Description: A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
Study NCT02711709 — intervention group
Intervention type: OTHER
Intervention: Computed tomography morphometrics
Description: A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
Study NCT02711709 — intervention group
Intervention type: OTHER
Intervention: Mobility Monitors
Description: Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
Study NCT03460262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cutiplast®
Description: Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
Study NCT03460262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO®
Description: PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
Study NCT03089905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
Study NCT03089905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
Study NCT03089905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
Study NCT03089905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
Study NCT01814241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label peanut OIT
Description: Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
Study NCT03502356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
Study NCT03241511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
Study NCT04145219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunotherapy tablet
Description: For daily administration (1 tablet per day)
Study NCT04145219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For daily administration (1 tablet per day)
Study NCT02722499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65.
Study NCT02722499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85
Study NCT02722499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Frequency Financial Incentive
Description: 1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150.
Study NCT04112212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW
Description: First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
Study NCT04112212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW
Description: Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.
Study NCT04112212 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab
Description: Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
Study NCT02472067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychologically - Based Physical Therapy
Description: Psychologically - Based Physical Therapy targeting risk factors for disability.
Study NCT02424578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Capsules low dose
Study NCT02424578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Capsules high dose
Study NCT04193644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Self-Compassion focussed exercises during walking training
Description: Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
Study NCT04193644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Walking training with moderate intensity
Study NCT05343728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastography
Description: Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
Study NCT05343728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile laboratory examination
Description: Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
Study NCT03869008 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore Sapphire
Description: gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation.
Study NCT03869008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore Sapphire
Description: gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation.
Study NCT03869008 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
Study NCT03937999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
Study NCT00324259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Study NCT00351429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid suture
Description: PGA suture used in Trabeculectomy surgery
Study NCT03665727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
Study NCT03665727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggestion
Description: The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
Study NCT03665727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
Study NCT01463085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-fat dairy
Description: Dietary Intervention of 3 servings per day of low-fat dairy
Study NCT01463085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Description: Dietary Intervention of 3 servings per day of low-fat dairy
Study NCT03854877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behaviour intervention
Description: The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
Study NCT03048006 — intervention group
Intervention type: PROCEDURE
Intervention: MRI with Dotarem
Study NCT02618070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Study NCT01436929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin 140mg 1tab bid for 8 weeks
Study NCT01436929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tab bid
Study NCT00662441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg taken 1 hours before sexual intercourse
Study NCT00845767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min).
Study NCT03401619 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.
Description: The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
Study NCT01120717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: capsules for inhalation, delivered by an SDDPI
Study NCT01120717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules for inhalation, delivered by an SDDPI
Study NCT02019797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.